BACKGROUND: An increasing body of evidence from neuropsychological and neuroimaging studies suggests that exposure to marijuana throughout adolescence disrupts key cortical maturation processes occurring during this developmental phase. GABA-modulating pharmacologic treatments that elevate brain GABA concentration recently have been shown to decrease withdrawal symptoms and improve executive functioning in marijuana-dependent adult subjects. The goal of this study was to investigate whether the lower ACC glutamate previously reported in adolescent chronic marijuana smokers is associated with lower ACC GABA levels. METHODS: Standard and metabolite-edited proton MRS data were acquired from adolescent marijuana users (N=13) and similarly aged non-using controls (N=16) using a clinical 3T MRI system. RESULTS: The adolescent marijuana-using cohort showed significantly lower ACC GABA levels (-22%, p=0.03), which paralleled significantly lower ACC glutamate levels (-14%, p=0.01). Importantly, the lower ACC GABA and glutamate levels detected in the adolescent cohort remained significant after controlling for age and sex. CONCLUSIONS: The present spectroscopic findings support functional neuroimaging data documenting cingulate dysfunction in marijuana-dependent adolescents. Glutamatergic and GABAergic abnormalities potentially underlie cingulate dysfunction in adolescent chronic marijuana users, and the opportunity for testing suitable pharmacologic treatments with a non-invasive pharmacodynamic evaluation exists.
BACKGROUND: An increasing body of evidence from neuropsychological and neuroimaging studies suggests that exposure to marijuana throughout adolescence disrupts key cortical maturation processes occurring during this developmental phase. GABA-modulating pharmacologic treatments that elevate brain GABA concentration recently have been shown to decrease withdrawal symptoms and improve executive functioning in marijuana-dependent adult subjects. The goal of this study was to investigate whether the lower ACC glutamate previously reported in adolescent chronic marijuana smokers is associated with lower ACC GABA levels. METHODS: Standard and metabolite-edited proton MRS data were acquired from adolescent marijuana users (N=13) and similarly aged non-using controls (N=16) using a clinical 3T MRI system. RESULTS: The adolescent marijuana-using cohort showed significantly lower ACC GABA levels (-22%, p=0.03), which paralleled significantly lower ACC glutamate levels (-14%, p=0.01). Importantly, the lower ACC GABA and glutamate levels detected in the adolescent cohort remained significant after controlling for age and sex. CONCLUSIONS: The present spectroscopic findings support functional neuroimaging data documenting cingulate dysfunction in marijuana-dependent adolescents. Glutamatergic and GABAergic abnormalities potentially underlie cingulate dysfunction in adolescent chronic marijuana users, and the opportunity for testing suitable pharmacologic treatments with a non-invasive pharmacodynamic evaluation exists.
Authors: Stephen M Smith; Mark Jenkinson; Mark W Woolrich; Christian F Beckmann; Timothy E J Behrens; Heidi Johansen-Berg; Peter R Bannister; Marilena De Luca; Ivana Drobnjak; David E Flitney; Rami K Niazy; James Saunders; John Vickers; Yongyue Zhang; Nicola De Stefano; J Michael Brady; Paul M Matthews Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: Matthew Geramita; Jan Willem van der Veen; Alan S Barnett; Antonina A Savostyanova; Jun Shen; Daniel R Weinberger; Stefano Marenco Journal: NMR Biomed Date: 2011-02-03 Impact factor: 4.044
Authors: Frederic Boy; C John Evans; Richard A E Edden; Krish D Singh; Masud Husain; Petroc Sumner Journal: Curr Biol Date: 2010-09-30 Impact factor: 10.834
Authors: Neha Arun Batra; Janette Seres-Mailo; Chris Hanstock; Peter Seres; Janisse Khudabux; François Bellavance; Glen Baker; Peter Allen; Philip Tibbo; Eric Hui; Jean-Michel Le Melledo Journal: Biol Psychiatry Date: 2007-12-03 Impact factor: 13.382
Authors: Andrew P Prescot; Steven R Miller; Gary Ingenito; Rebekah S Huber; Douglas G Kondo; Perry F Renshaw Journal: Neuropsychopharmacology Date: 2017-07-25 Impact factor: 7.853
Authors: Sotirios Posporelis; Jennifer M Coughlin; Anouk Marsman; Subechhya Pradhan; Teppei Tanaka; Hongxing Wang; Mark Varvaris; Rebecca Ward; Cecilia Higgs; Jamie A Edwards; Candice N Ford; Pearl K Kim; Ashley M Lloyd; Richard A E Edden; David J Schretlen; Nicola G Cascella; Peter B Barker; Akira Sawa Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-04-21
Authors: Marisa M Silveri; Alecia D Dager; Julia E Cohen-Gilbert; Jennifer T Sneider Journal: Neurosci Biobehav Rev Date: 2016-07-01 Impact factor: 8.989
Authors: Mohini Ranganathan; Joao P De Aquino; Jose A Cortes-Briones; Rajiv Radhakrishnan; Brian Pittman; Savita Bhakta; Deepak C D'Souza Journal: Psychopharmacology (Berl) Date: 2019-06-11 Impact factor: 4.530